fig2
![Pharmacogenetics of anticancer monoclonal antibodies](https://image.oaes.cc/3be78288-ed85-4cfe-b7b2-64bbd49dca74/3004.fig.2.jpg)
Figure 2. Mechanism of anticancer activity of anti-EGFR mAbs. Cetuximab and panitumumab bind to EGF receptors, thus preventing further signalling transduction via PI3K/mTOR and RAS/ERK pathways. Inactivation of growth signalling pathways prevents cell proliferation and survival. EGFR: epidermal growth factor receptor; mAbs: monoclonal antibodies